Description

PHARMACEUTICAL FORM
Injectable suspension. Homogeneous opalescent suspension.

SPECIES
Indications
For active immunization of horses from 5 months of age against West Nile disease by reducing the number of viremic horses. If clinical signs are manifested, their duration and severity are reduced.

– Establishment of immunity: 4 weeks after the first dose of the primary vaccination. To achieve full protection, the two-dose schedule program should be followed.
– Duration of immunity: 1 year after the complete primary vaccination with two injections.

DOSE / APPLICATION / ADMINISTRATION
Route of administration: Intramuscular.
Dosage: Administer 1 dose of 1ml by intramuscular injection, preferably in the neck, according to the following schedule:

* Primary vaccination: first injection at 5 months of age; second injection after 4 – 6 weeks.
* Booster injection: a sufficient degree of protection after the annual booster injection with a single 1ml dose, although this schedule has not been fully validated.

It can be used during pregnancy and lactation.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1ml contains:
Active substance:
Recombinant canaripox virus West Nile (vCP2017): 6,0 a 7,8 log10 DICC*50
*Infectious dose 50% cell culture

Adjuvant:
Carbomer: 4mg

Presentation
2 vials with 1 dose